NCT06798727View on ClinicalTrials.gov

Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

March 20, 2027

Study Completion Date

November 30, 2027

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

SMUP-IA-01(low-dose)

A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

BIOLOGICAL

SMUP-IA-01(mid-dose)

A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

DRUG

High Hyal Plus

A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)

Trial Locations (5)

Unknown

Seoul Nation University Bundang Hospital, Gyeonggi-do

Gangnam Severance Hospital, Seoul

Korea University Anam Hospita, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

All Listed Sponsors
lead

Medipost Co Ltd.

INDUSTRY